A structural at~las of kinases inhibited by clinically approved drugs

Methods in Enzymology

Volumn 548, Issue C, 2014, Pages 23-67

  Wang, Qi ^a,b   Zorn, Julie A ^a,b   Kuriyan, John ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Crystal structure; Drug; Inhibitor; Kinase

Indexed keywords

ABELSON KINASE; ADENOSINE TRIPHOSPHATE; AFATINIB; AXITINIB; BCR ABL PROTEIN; BOSUTINIB; CRIZOTINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IMATINIB; JANUS KINASE; LAPATINIB; NILOTINIB; PAZOPANIB; PONATINIB; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN RET; REGORAFENIB; SORAFENIB; STAUROSPORINE; SUNITINIB; TOFACITINIB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR; VEMURAFENIB;

BINDING AFFINITY; BINDING SITE; CATALYSIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG APPROVAL; DRUG DESIGN; DRUG DETERMINATION; DRUG RESISTANCE; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME MECHANISM; FOCAL ADHESION; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HUMAN; INHIBITION CONSTANT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FAMILY; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; AMINO ACID SEQUENCE; BIOCATALYSIS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; ENZYME ACTIVE SITE; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; PROTEIN PROCESSING;

ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; BIOCATALYSIS; CATALYTIC DOMAIN; CONSERVED SEQUENCE; HUMANS; MODELS, MOLECULAR; MUTATION; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84925457876     PISSN: 00766879     EISSN: 15577988     Source Type: Book Series    
DOI: 10.1016/B978-0-12-397918-6.00002-1     Document Type: Chapter

References (156)

1. J.A. Adams Kinetic and catalytic mechanisms of protein kinases Chemical Reviews 101 2001 2271 2290
2. T. Anastassiadis, S.W. Deacon, K. Devarajan, H. Ma, and J.R. Peterson Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nature Biotechnology 29 2011 1039 1045
3. A.J. Barker, K.H. Gibson, W. Grundy, A.A. Godfrey, J.J. Barlow, and M.P. Healy Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorganic & Medicinal Chemistry Letters 11 2001 1911 1914
4. S.F. Barnett, D. Defeo-Jones, S. Fu, P.J. Hancock, K.M. Haskell, and R.E. Jones Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors The Biochemical Journal 385 2005 399 408
5. S. Betzi, R. Alam, M. Martin, D.J. Lubbers, H. Han, and S.R. Jakkaraj Discovery of a potential allosteric ligand binding site in CDK2 ACS Chemical Biology 6 2011 492 501
6. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 2001 355 365
7. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, and H. Cho Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599
8. G. Bollag, J. Tsai, J. Zhang, C. Zhang, P. Ibrahim, and K. Nolop Vemurafenib: The first drug approved for BRAF-mutant cancer Nature Reviews. Drug Discovery 11 2012 873 886
9. D.H. Boschelli, F. Ye, Y.D. Wang, M. Dutia, S.L. Johnson, and B. Wu Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity Journal of Medicinal Chemistry 44 2001 3965 3977
10. M.R. Brewer, S.H. Choi, D. Alvarado, K. Moravcevic, A. Pozzi, and M.A. Lemmon The juxtamembrane region of the EGF receptor functions as an activation domain Molecular Cell 34 2009 641 651
11. R. Capdeville, E. Buchdunger, J. Zimmermann, and A. Matter Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug Nature Reviews. Drug Discovery 1 2002 493 502
12. F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, T. Giampaolo, and G. Vecchio ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Research 62 2002 7284 7290
13. M. Castagna, Y. Takai, K. Kaibuchi, K. Sano, U. Kikkawa, and Y. Nishizuka Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters The Journal of Biological Chemistry 257 1982 7847 7851
14. L.H. Chao, M.M. Stratton, I.-H. Lee, O.S. Rosenberg, J. Levitz, and D.J. Mandell A mechanism for tunable autoinhibitionin the structure of a human Ca Cell 146 2011 732 745
15. Y.-Y. Chiu, C.-T. Lin, J.-W. Huang, K.-C. Hsu, J.-H. Tseng, and S.-R. You KIDFamMap: A database of kinase-inhibitor-disease family maps for kinase inhibitor selectivity and binding mechanisms Nucleic Acids Research 41 2013 D430 D440
16. E.N. Churchill, N. Qvit, and D. Mochly-Rosen Rationally designed peptide regulators of protein kinase C Trends in Endocrinology and Metabolism 20 2009 25 33
17. P. Cohen Protein kinases - The major drug targets of the twenty-first century? Nature Reviews. Drug Discovery 1 2002 309 315
18. P. Cohen, and D.R. Alessi Kinase drug discovery - What's next in the field? ACS Chemical Biology 8 2013 96 104
19. M.S. Cohen, C. Zhang, K.M. Shokat, and J. Taunton Structural bioinformatics-based design of selective, irreversible kinase inhibitors Science 308 2005 1318 1321
20. M.S. Collett, and R.L. Erikson Protein kinase activity associated with the avian sarcoma virus src gene product Proceedings of the National Academy of Sciences of the United States of America 75 1978 2021 2024
21. A.C. Dar, M.S. Lopez, and K.M. Shokat Brief communication Chemistry & Biology 15 2008 1015 1022
22. A.C. Dar, and K.M. Shokat The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling Annual Review of Biochemistry 80 2011 769 795
23. J. Das, P. Chen, D. Norris, R. Padmanabha, J. Lin, and R.V. Moquin 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor Journal of Medicinal Chemistry 49 2006 6819 6832
24. H. Daub, K. Specht, and A. Ullrich Strategies to overcome resistance to targeted protein kinase inhibitors Nature Reviews. Drug Discovery 3 2004 1001 1010
25. S.P. Davies, H. Reddy, M. Caivano, and P. Cohen Specificity and mechanism of action of some commonly used protein kinase inhibitors The Biochemical Journal 351 2000 95 105
26. M.I. Davis, J.P. Hunt, S. Herrgard, Pietro Ciceri, L.M. Wodicka, and G. Pallares Comprehensive analysis of kinase inhibitor selectivity Nature Biotechnology 29 2011 1046 1051
27. B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, and S. Fanning Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr|[ndash]|Abl positive cells Nature Medicine 2 1996 561 566
28. W. Eckhart, M.A. Hutchinson, and T. Hunter An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates Cell 18 1979 925 933
29. L.M. Ellis, and D.J. Hicklin VEGF-targeted therapy: Mechanisms of anti-tumour activity Nature Reviews. Cancer 8 2008 579 591
30. M. Engel, V. Hindie, L.A. Lopez-Garcia, A. Stroba, F. Schaeffer, and I. Adrian Allosteric activation of the protein kinase PDK1 with low molecular weight compounds The EMBO Journal 25 2006 5469 5480
31. R.A. Engh, and D. Bossemeyer Structural aspects of protein kinase control - Role of conformational flexibility Pharmacology and Therapeutics 93 2002 99 111
32. M.A. Fabian, W.H. Biggs, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, and M.G. Benedetti A small molecule-kinase interaction map for clinical kinase inhibitors Nature Biotechnology 23 2005 329 336
33. K.T. Flaherty Sorafenib in renal cell carcinoma Clinical Cancer Research 13 2007 747s 752s
34. J.E. Frampton Lapatinib: A review of its use in the treatment of HER2-overexpressing, trastuzumab-refractory, advanced or metastatic breast cancer Drugs 69 2009 2125 2148
35. D.W. Fry, A.J. Kraker, A. McMichael, L.A. Ambroso, J.M. Nelson, and W.R. Leopold A specific inhibitor of the epidermal growth factor receptor tyrosine kinase Science 265 1994 1093 1095
36. J. Gao, B.H. Ha, H.J. Lou, E.M. Morse, R. Zhang, and D.A. Calderwood Substrate and inhibitor specificity of the type II p21-activated kinase, pak6 PLoS One 8 2013 e77818
37. M.J. Garnett, S. Rana, H. Paterson, D. Barford, and R. Marais Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization Molecular Cell 20 2005 963 969
38. J.M. Golas, K. Arndt, C. Etienne, J. Lucas, D. Nardin, and J. Gibbons SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice Cancer Research 63 2003 375 381
39. C.M. Gower, M.E.K. Chang, and D.J. Maly Bivalent inhibitors of protein kinases Critical Reviews in Biochemistry and Molecular Biology 49 2014 102 115
40. J. Griffith, J. Black, C. Faerman, L. Swenson, M. Wynn, and F. Lu The structural basis for autoinhibition of FLT3 by the juxtamembrane domain Molecular Cell 13 2004 169 178
41. J.H. Hanke, J.P. Gardner, R.L. Dow, P.S. Changelian, W.H. Brissette, and E.J. Weringer Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation The Journal of Biological Chemistry 271 1996 695 701
42. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, and R. Alvarado RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
43. L.F. Hennequin, E.S.E. Stokes, A.P. Thomas, C. Johnstone, P.A. Ple, and D.J. Ogilvie Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors Journal of Medicinal Chemistry 45 2002 1300 1312
44. S. Hirota, K. Isozaki, Y. Moriyama, K. Hashimoto, T. Nishida, and S. Ishiguro Gain-of-function mutations of c-Kit in human gastrointestinal stromal tumors Science 279 1998 577 580
45. J. Hu, E.C. Stites, H. Yu, E.A. Germino, H.S. Meharena, and P.J.S. Stork Allosteric activation of functionally asymmetric RAF kinase dimers Cell 154 2013 1036 1046
46. S.R. Hubbard Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog The EMBO Journal 16 1997 5572 5581
47. S.R. Hubbard Juxtamembrane autoinhibition in receptor tyrosine kinases Nature Reviews. Molecular Cell Biology 5 2004 464 471
48. S.R. Hubbard, M. Mohammadi, and J. Schlessinger Autoregulatory mechanisms in protein-tyrosine kinases The Journal of Biological Chemistry 273 1998 11987 11990
49. S.R. Hubbard, L. Wei, L. Ellis, and W.A. Hendrickson Crystal structure of the tyrosine kinase domain of the human insulin receptor Nature 372 1994 746 754
50. T. Hunter Protein kinases and phosphatases: The yin and yang of protein phosphorylation and signaling Cell 80 1995 225 236
51. M. Huse, and J. Kuriyan The conformational plasticity of protein kinases Cell 109 2002 275 282
52. P.D. Jeffrey, A.A. Russo, K. Polyak, E. Gibbs, J. Hurwitz, and J. Massagué Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex Nature 376 1995 313 320
53. L.N. Johnson The regulation of protein phosphorylation Biochemical Society Transactions 37 2009 627 641
54. L.N. Johnson Protein kinase inhibitors: Contributions from structure to clinical compounds Quarterly Reviews of Biophysics 42 2009 1
55. N. Jura, N.F. Endres, K. Engel, S. Deindl, R. Das, and M.H. Lamers Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment Cell 137 2009 1293 1307
56. N. Jura, X. Zhang, N.F. Endres, M.A. Seeliger, T. Schindler, and J. Kuriyan Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms Molecular Cell 42 2011 9 22
57. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, and B.T. Campbell A quantitative analysis of kinase inhibitor selectivity Nature Biotechnology 26 2008 127 132
58. Z.A. Knight, H. Lin, and K.M. Shokat Nature Reviews Cancer 10 2 2010 130 137
59. Z.A. Knight, and K.M. Shokat Features of selective kinase inhibitors Chemistry & Biology 12 2005 621 637
60. D.R. Knighton, J.H. Zheng, L.F. Ten Eyck, V.A. Ashford, N.H. Xuong, and S.S. Taylor Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 1991 407 414
61. P.P. Knowles, J. Murray-Rust, S. Kjaer, R.P. Scott, S. Hanrahan, and M. Santoro Structure and chemical inhibition of the RET tyrosine kinase domain The Journal of Biological Chemistry 281 44 2006 33577 33587
62. A.P. Kornev, N.M. Haste, S.S. Taylor, and L.F.T. Eyck Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proceedings of the National Academy of Sciences of the United States of America 103 2006 17783 17788
63. A.P. Kornev, S.S. Taylor, and L.F. Ten Eyck A helix scaffold for the assembly of active protein kinases Proceedings of the National Academy of Sciences 105 2008 14377 14382
64. R. Krishnamurty, and D.J. Maly Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors ACS Chemical Biology 5 2010 121 138
65. J. Kuriyan, and D. Eisenberg The origin of protein interactions and allostery in colocalization Nature 450 2007 983 990
66. A.K. Kutach, A.G. Villaseñor, D. Lam, C. Belunis, C. Janson, and S. Lok Crystal structures of IL-2-inducible T cell kinase complexed with inhibitors: insights into rational drug design and activity regulation Chemical Biology & Drug Design 76 2010 154 163
67. A.D. Laird, P. Vajkoczy, L.K. Shawver, A. Thurnher, C. Liang, and M. Mohammadi SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors Cancer Research 60 2000 4152 4160
68. B. Laudet, C. Barette, V. Dulery, O. Renaudet, P. Dumy, and A. Metz Structure-based design of small peptide inhibitors of protein kinase CK2 subunit interaction The Biochemical Journal 408 2007 363 373
69. A.M. Lawrie, M.E. Noble, P. Tunnah, N.R. Brown, L.N. Johnson, and J.A. Endicott Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 Nature Structural Biology 4 1997 796 801
70. M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
71. N.M. Levinson, and S.G. Boxer A conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivity Nature Chemical Biology 10 2014 127 132
72. A.D. Levinson, H. Oppermann, L. Levintow, H.E. Varmus, and J.M. Bishop Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein Cell 15 1978 561 572
73. A. Levitzki Protein kinase inhibitors as a therapeutic modality Accounts of Chemical Research 36 2003 462 469
74. A. Levitzki, and A. Gazit Tyrosine kinase inhibition: An approach to drug development Science 267 1995 1782 1788
75. A. Levitzki, and E. Mishani Tyrphostins and other tyrosine kinase inhibitors Annual Review of Biochemistry 75 2006 93 109
76. P. Littlefield, M.M. Moasser, and N. Jura An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase Chemistry & Biology 21 2014 453 458
77. Y. Liu, and N.S. Gray Rational design of inhibitors that bind to inactive kinase conformations Nature Chemical Biology 2 2006 358 364
78. Q. Liu, Y. Sabnis, Z. Zhao, T. Zhang, S.J. Buhrlage, and L.H. Jones Developing irreversible inhibitors of the protein kinase cysteinome Chemistry & Biology 20 2013 146 159
79. N.B. Lydon, and B.J. Druker Lessons learned from the development of imatinib Leukemia Research 28 Suppl. 1 2004 S29 S38
80. P.W. Manley, S.W. Cowan-Jacob, and J. Mestan Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia Biochimica Et biophysica Acta 1754 2005 3 13
81. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
82. M.P. Martin, R. Alam, S. Betzi, D.J. Ingles, J.Y. Zhu, and E. Schönbrunn A novel approach to the discovery of small-molecule ligands of CDK2 ChemBioChem 13 2012 2128 2136
83. M. McTigue, B.W. Murray, J.H. Chen, Y.-L. Deng, J. Solowiej, and R.S. Kania Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors Proceedings of the National Academy of Sciences 109 2012 18281 18289
84. M. Mohammadi, G. McMahon, L. Sun, C. Tang, P. Hirth, and B.K. Yeh Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors Science 276 1997 955 960
85. M. Mohammadi, J. Schlessinger, and S.R. Hubbard Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism Cell 86 1996 577 587
86. C.D. Mol, D.R. Dougan, T.R. Schneider, R.J. Skene, M.L. Kraus, and D.N. Scheibe Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase The Journal of Biological Chemistry 279 2004 31655 31663
87. J.D. Moyer, E.G. Barbacci, K.K. Iwata, L. Arnold, B. Boman, and A. Cunningham Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Research 57 1997 4838 4848
88. B. Nagar, W.G. Bornmann, P. Pellicena, T. Schindler, D.R. Veach, and W.T. Miller Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Research 62 2002 4236 4243
89. B. Nagar, O. Hantschel, M.A. Young, K. Scheffzek, D.R. Veach, and W. Bornmann Structural basis for the autoinhibition of c-Abl tyrosine kinase Cell 112 2003 859 871
90. B. Nolen, S. Taylor, and G. Ghosh Regulation of protein kinases; controlling activity through activation segment conformation Molecular Cell 15 2004 661 675
91. Y. Oguro, D.R. Cary, N. Miyamoto, M. Tawada, H. Iwata, and H. Miki Design, synthesis, and evaluation of novel VEGFR2 kinase inhibitors: discovery of [1,2,4]triazolo[1,5-a]pyridine derivatives with slow dissociation kinetics Bioorganic & Medicinal Chemistry 21 2013 4714 4729
92. T. O'Hare, W.C. Shakespeare, X. Zhu, C.A. Eide, V.M. Rivera, and F. Wang Ap24534, a Pan-Bcr-Abl inhibitor for chronic myeloid leukemia, potently inhibits the t315i mutant and overcomes mutation-based resistance Cancer Cell 16 2009 401 412
93. J.F. Ohren, H. Chen, A. Pavlovsky, C. Whitehead, E. Zhang, and P. Kuffa Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nature Structural & Molecular Biology 11 2004 1192 1197
94. S. Omura, Y. Iwai, A. Hirano, A. Nakagawa, J. Awaya, and H. Tsuchya A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization The Journal of Antibiotics 30 1977 275 282
95. S. Omura, Y. Sasaki, Y. Iwai, and H. Takeshima Staurosporine, a potentially important gift from a microorganism The Journal of Antibiotics 48 1995 535 548
96. N. Osherov, and A. Levitzki Epidermal-growth-factor-dependent activation of the src-family kinases European Journal of Biochemistry 225 1994 1047 1053
97. K. Parang, J.H. Till, A.J. Ablooglu, R.A. Kohanski, S.R. Hubbard, and P.A. Cole Mechanism-based design of a protein kinase inhibitor Nature Structural Biology 8 2001 37 41
98. J.H. Park, Y. Liu, M.A. Lemmon, and R. Radhakrishnan Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain The Biochemical Journal 448 2012 417 423
99. C.E. Paulsen, T.H. Truong, F.J. Garcia, A. Homann, V. Gupta, and S.E. Leonard Peroxide-dependent sulfenylation of the eGFr catalytic site enhances kinase activity Nature Chemical Biology 8 2011 57 64
100. T. Pawson, and T. Hunter Signal transduction and growth control in normal and cancer cells Current Opinion in Genetics & Development 4 1994 1 4
101. T. Pawson, and M. Kofler Kinome signaling through regulated protein-protein interactions in normal and cancer cells Current Opinion in Cell Biology 21 2009 147 153
102. T. Pawson, and J.D. Scott Signaling through scaffold, anchoring, and adaptor proteins Science 278 1997 2075 2080
103. P. Pellicena, and J. Kuriyan Protein-protein interactions in the allosteric regulation of protein kinases Current Opinion in Structural Biology 16 2006 702 709
104. L. Prade, R.A. Engh, A. Girod, V. Kinzel, R. Huber, and D. Bossemeyer Staurosporine-induced conformational changes of cAMP-dependent protein kinase catalytic subunit explain inhibitory potential Structure 5 1997 1627 1637
105. L.L. Remsing Rix, U. Rix, J. Colinge, O. Hantschel, K.L. Bennett, and T. Stranzl Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells Leukemia 23 2009 477 485
106. B.I. Rini Temsirolimus, an inhibitor of mammalian target of rapamycin Clinical Cancer Research 14 2008 1286 1290
107. D.W. Rusnak, K. Affleck, S.G. Cockerill, C. Stubberfield, R. Harris, and M. Page The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: Potential therapy for cancer Cancer Research 61 2001 7196 7203
108. C.L. Sawyers Opportunities and challenges in the development of kinase inhibitor therapy for cancer Genes & Development 17 2003 2998 3010
109. T. Schindler, W. Bornmann, P. Pellicena, W.T. Miller, B. Clarkson, and J. Kuriyan Structural mechanism for STI-571 inhibition of abelson tyrosine kinase Science 289 2000 1938 1942
110. T. Schindler, F. Sicheri, A. Pico, A. Gazit, A. Levitzki, and J. Kuriyan Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor Molecular Cell 3 1999 639 648
111. M.M. Schittenhelm, S. Shiraga, A. Schroeder, A.S. Corbin, D. Griffith, and F.Y. Lee Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies Cancer Research 66 2006 473 481
112. P.A. Schwartz, and B.W. Murray Protein kinase biochemistry and drug discovery Bioorganic Chemistry 39 2011 192 210
113. J.S. Sebolt-Leopold, D.T. Dudley, R. Herrera, K. Van Becelaere, A. Wiland, and R.C. Gowan Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo Nature Medicine 5 1999 810 816
114. M.A. Seeliger, B. Nagar, F. Frank, X. Cao, M.N. Henderson, and J. Kuriyan c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty Structure 15 2007 299 311
115. M.A. Seeliger, P. Ranjitkar, C. Kasap, Y. Shan, D.E. Shaw, and N.P. Shah Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations Cancer Research 69 2009 2384 2392
116. Y. Shan, M.P. Eastwood, X. Zhang, E.T. Kim, A. Arkhipov, and R.O. Dror Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization Cell 149 2012 860 870
117. Y. Shan, M.A. Seeliger, M.P. Eastwood, F. Frank, H. Xu, and M.Ø. Jensen A conserved protonation-dependent switch controls drug binding in the Abl kinase Proceedings of the National Academy of Sciences 106 2009 139 144
118. A.S. Shaw, A.P. Kornev, J. Hu, L.G. Ahuja, and S.S. Taylor Kinases and pseudokinases: Lessons from RAF Molecular and Cellular Biology 34 2014 1538 1546
119. F. Sicheri, I. Moarefi, and J. Kuriyan Crystal structure of the Src family tyrosine kinase Hck Nature 385 1997 602 609
120. J.R. Simard, S. Klüter, C. Grütter, M. Getlik, M. Rabiller, and H.B. Rode A new screening assay for allosteric inhibitors of cSrc Nature Chemical Biology 5 2009 394 396
121. F. Solca, G. Dahl, A. Zoephel, G. Bader, M. Sanderson, and C. Klein Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker The Journal of Pharmacology and Experimental Therapeutics 343 2012 342 350
122. J. Solowiej, S. Bergqvist, M.A. McTigue, T. Marrone, T. Quenzer, and M. Cobbs Characterizing the effects of the juxtamembrane domain on vascular endothelial growth factor receptor-2 enzymatic activity, autophosphorylation, and inhibition by axitinib Biochemistry 48 2009 7019 7031
123. J. Stamos, M.X. Sliwkowski, and C. Eigenbrot Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor The Journal of Biological Chemistry 277 2002 46265 46272
124. J.M. Steichen, G.H. Iyer, S. Li, S.A. Saldanha, M.S. Deal, and V.L. Woods Global consequences of activation loop phosphorylation on protein kinase A Journal of Biological Chemistry 285 2010 3825 3832
125. L. Sun, C. Liang, S. Shirazian, Y. Zhou, T. Miller, and J. Cui Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase Journal of Medicinal Chemistry 46 2003 1116 1119
126. L. Sun, N. Tran, C. Liang, F. Tang, A. Rice, and R. Schreck Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases Journal of Medicinal Chemistry 42 1999 5120 5130
127. L. Sun, N. Tran, F. Tang, H. App, P. Hirth, and G. McMahon Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases Journal of Medicinal Chemistry 41 1998 2588 2603
128. T. Tamaoki, H. Nomoto, I. Takahashi, Y. Kato, M. Morimoto, and F. Tomita Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase Biochemical and Biophysical Research Communications 135 1986 397 402
129. J.S. Tokarski, J.A. Newitt, C.Y.J. Chang, J.D. Cheng, M. Wittekind, and S.E. Kiefer The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants Cancer Research 66 2006 5790 5797
130. L.M. Toledo, and N.B. Lydon Structures of staurosporine bound to CDK2 and cAPK - New tools for structure-based design of protein kinase inhibitors Structure 5 1997 1551 1556
131. N. Tomita, Y. Hayashi, S. Suzuki, Y. Oomori, Y. Aramaki, and Y. Matsushita Structure-based discovery of cellular-active allosteric inhibitors of FAK Bioorganic & Medicinal Chemistry Letters 23 2013 1779 1785
132. P. Traxler, and P. Furet Strategies toward the design of novel and selective protein tyrosine kinase inhibitors Pharmacology and Therapeutics 82 1999 195 206
133. J. Tsai, J.T. Lee, W. Wang, J. Zhang, H. Cho, and S. Mamo Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proceedings of the National Academy of Sciences 105 2008 3041 3046
134. O.P.J. van Linden, A.J. Kooistra, R. Leurs, I.J.P. de Esch, and C. de Graaf KLIFS: A knowledge-based structural database to navigate kinase-ligand interaction space Journal of Medicinal Chemistry 57 2014 249 277
135. B. Vogelstein, and K.W. Kinzler Cancer genes and the pathways they control Nature Medicine 10 2004 789 799
136. P.T.C. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, and V.M. Good Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
137. H. Wang, T.A. Kadlecek, B.B. Au-Yeung, H.E.S. Goodfellow, L.Y. Hsu, and T.S. Freedman ZAP-70: An essential kinase in T-cell signaling Cold Spring Harbor Perspectives in Biology 2 2010 a002279
138. W.H. Ward, P.N. Cook, A.M. Slater, D.H. Davies, G.A. Holdgate, and L.R. Green Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor Biochemical Pharmacology 48 1994 659 666
139. E. Weisberg, P.W. Manley, W. Breitenstein, J. Brüggen, S.W. Cowan-Jacob, and A. Ray Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 2005 129 141
140. E. Weisberg, P.W. Manley, S.W. Cowan-Jacob, A. Hochhaus, and J.D. Griffin Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia Nature Reviews. Cancer 7 2007 345 356
141. S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, and R.A. Smith Discovery and development of sorafenib: A multikinase inhibitor for treating cancer Nature Reviews. Drug Discovery 5 2006 835 844
142. S.M. Wilhelm, J. Dumas, L. Adnane, M. Lynch, C.A. Carter, and G. Schütz Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity International Journal of Cancer 129 2011 245 255
143. J. Wityak, J. Das, R.V. Moquin, Z. Shen, J. Lin, and P. Chen Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck) Bioorganic & Medicinal Chemistry Letters 13 2003 4007 4010
144. E.R. Wood, A.T. Truesdale, O.B. McDonald, D. Yuan, A. Hassell, and S.H. Dickerson A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Research 64 2004 6652 6659
145. W.-I. Wu, W.C. Voegtli, H.L. Sturgis, F.P. Dizon, G.P.A. Vigers, and B.J. Brandhuber Crystal structure of human AKT1 with an allosteric inhibitor reveals a new mode of kinase inhibition PLoS One 5 2010 e12913
146. L.E. Wybenga-Groot, B. Baskin, S.H. Ong, J. Tong, T. Pawson, and F. Sicheri Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region Cell 106 2001 745 757
147. W. Xu, S.C. Harrison, and M.J. Eck Three-dimensional structure of the tyrosine kinase c-Src Nature 385 1997 595 602
148. H. Yamaguchi, and W.A. Hendrickson Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation Nature 384 1996 484 489
149. C.H. Yun, T.J. Boggon, Y. Li, M.S. Woo, H. Greulich, and M.J. Eck Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11 3 2007 217 227
150. X. Zhang, J. Gureasko, K. Shen, P.A. Cole, and J. Kuriyan An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125 2006 1137 1149
151. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nature Reviews. Cancer 9 2009 28 39
152. Z. Zhao, H. Wu, L. Wang, Y. Liu, S. Knapp, and Q. Liu Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery? ACS Chemical Biology 6 2014 1230 1241
153. J. Zheng, E.A. Trafny, D.R. Knighton, N.H. Xuong, S.S. Taylor, and L.F. Ten Eyck 2.2 A refined crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MnATP and a peptide inhibitor Acta Crystallographica. Section D, Biological Crystallography 49 1993 362 365
154. T. Zhou, L. Commodore, W.-S. Huang, Y. Wang, M. Thomas, and J. Keats Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): Lessons for overcoming kinase inhibitor resistance Chemical Biology & Drug Design 77 2011 1 11
155. J. Zimmermann, E. Buchdunger, H. Mett, T. Meyer, and N.B. Lydon Potent and selective inhibitors of the Abl-kinase: Phenylamino-pyrimidine (PAP) derivatives Bioorganic & Medicinal Chemistry Letters 7 1997 187 192
156. J. Zimmermann, E. Buchdunger, H. Mett, T. Meyer, N.B. Lydon, and P. Traxler Phenylamino-pyrimidine (PAP)-derivatives: A new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors Bioorganic & Medicinal Chemistry Letters 6 1996 1221 1226